Date: 22nd March 2018 Our Ref: FANitaminMGPG/Mar18 Enquiries to Frances Adamson Extension: Direct Line: f.adamsonanhs.

Similar documents
This letter authorises the extended use of the following guidance until 1st June 2019:

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension Direct Line tadamson(anhs.

Administration of High Dose Intra- Muscular Vitamin Supplements for Patients Undergoing Alcohol Detoxification. Standard Operating Procedure

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication

Consultation Group: Lead Community Dietitians Aberdeen, Aberdeenshire and Moray CHP. Review Date: October Uncontrolled when printed.

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults

NHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults

Guidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings

This letter authorises the extended use of the following protocol until 1st September 2018:

NHSG/Pol/OralNut/MGPG639

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

PABRINEX PRESCRIBING PROTOCOL JULY This policy supersedes all previous policies for medically assisted community alcohol withdrawal

Alcohol Detoxification (Inpatient) Prescribing Guidelines

Consultation Group: Cardiology Consultants Clinical lead for cardiology: Dr Andrew Hannah. Review Date: Uncontrolled when printed.

This letter authorises the extended use of the following guidance until 1st December 2018:

Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian

GUIDANCE NOTES. DIETETIC RISK ASSESSMENT FOR REFEEDING RECOMMENDED MEAL PLANS When commencing re-feeding: NICE (2006)

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

I write in response to your request for information in relation to pharmacy drug guidelines within NHS Lothian.

Standard Operating Procedure for the Prevention and Treatment of Oral Mucositis

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

ALCOHOL WITHDRAWAL GUIDELINES

Document Details. Patient Group Direction

Acute Alcohol Withdrawal Protocol

Guidelines for the In-Patient Management of Alcohol Withdrawal at Frimley Park Hospital NHS Foundation Trust

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

PATIENT GROUP DIRECTION PROCEDURE

Pharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V01. Planned review: December 2017

Guidance For The Development And Implementation Of Patient Group Directions (PGDs) For Staff Working Within NHS Grampian. Consultation Group:

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Guidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian

Consultation Group: See relevant page in the PGD. Review Date: October 2017

concentrate intravenous solution and other strong potassium solutions

Prescribing for substance misuse: alcohol detoxification. Clinical background

Guideline scope Neonatal parenteral nutrition

Document Details. Patient Group Direction

PATIENT GROUP DIRECTION (PGD)

Does the patient need an enteral feed out of hours?

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Nutrition support in adults: oral supplements, enteral and parenteral feeding.

IMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY

Guidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian. Consultation Group:

NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease

Out of Hours Emergency Enteral Feeding Regimen (Including Risk Reduction for Re-feeding Syndrome)

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Pharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V02. Planned review: Dec 2020

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

PATIENT SAFETY ALERT

INCREASING INCIDENCE OF KORSAKOFF'S PSYCHOSIS IN THE EAST END OF GLASGOW

Ketorolac injection. Supportive care

Acute management of severe malnutrition. Dr Simon Gabe St Mark s Hospital, London

Patient Group Directions Policy

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion

Understanding Alcohol Misuse in Scotland HARMFUL DRINKING. 4: The use of intravenous B vitamins

Community alcohol detoxification in primary care

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

PACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)

Appropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community

Guideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology

Patient Group Direction For The Supply Of Levonorgestrel For Emergency Hormonal Contraception By Pharmacists Working Within NHS Grampian

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

SHARED CARE GUIDELINE

Guidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings

1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate.

CAUTION: You must refer to the intranet for the most recent version of this procedural document.

Developed By Name Signature Date

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

Patient Information Leaflet: Information for users

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection

BNF 9: Blood and Nutrition

NHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Common Infusions for Neonatal Use

PHARMACOLOGY AND PHARMACOKINETICS

This document expires on Patient Group Direction No. VI 11

Refeeding Syndrome Guideline

ACMN WORKSHOP. Injectable Nutrients B Vitamins Theory. Dr Ian Dettman Colombia Nov 2010

From the Deputy Chief Medical Officer / Chief Dental Officer Dr Anne Kilgallen / Simon Reid. Circular HSC (SQSD) (NICE NG30) 37/16

Patient Group Directions (PGDs)

Guidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics

DR J HARTY / DR CM RITCHIE / DR M GIBBONS

NAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know

Refeeding syndrome a practical approach

Patient Information Leaflet: Information for users

VITAMIN D DEFICIENCY IN CHILDREN AND ADULTS: TREATMENT AND PROPHYLAXIS GUIDELINE

University Hospitals of Leicester NHS Trust

All Saints First School Administering of Medicines Policy

Index No: MMG11/1. Version: 1. Date ratified: 12 th November 2013

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

Trust Guideline for the Management and Administration of Intravenous Iron in Adults under the Gastroenterology Directorate

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Initiation of Clozapine Treatment Community Patients

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

This document expires on Patient Group Direction No. VI 5

Transcription:

NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 22nd March 2018 Our Ref: FANitaminMGPG/Mar18 Enquiries to Frances Adamson Extension: 56689 Direct Line: 01224 556689 Email: f.adamsonanhs.net Dear Colleague This letter authorises the extended use of the following guidance until 1st September 2018: NHS Grampian (Acute Sector) Guidance for the prescribing of vitamin and mineral supplements for hospitalised patients with a history of excess alcohol consumption The review of this Guideline is currently underway and the updated version will be available later in 2018. If you have any queries regarding this please do not hesitate to contact the Pharmacy and Medicines Directorate. Yours sincerely Sandy Thomson Interim Chair of the Medicines Guidelines and Policies Group

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245 This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Title: NHS Grampian (Acute Sector) Guidance for the prescribing of vitamin and mineral supplements for hospitalised patients with a history of excess alcohol consumption Unique Identifier: Replaces: Lead Author/Co-ordinator: Subject (as per document registration categories): Key word(s): Process Document: Policy, Protocol, Procedure or Guideline Document application: Purpose/description: NHSG/Guid/VitSupAC/MGPG503 N/A new document Lynne Crighton, Clinical Pharmacist Guideline Alcohol, vitamin, mineral, supplement, Pabrinex, thiamine, Wernicke-Korsakoff, decompensated, liver, disease, Forceval, Abidec Guideline NHS Grampian (Acute Sector) This guidance provides information on the use of parenteral vitamin supplementation for hospitalised patients within the acute sector with a history of alcohol excess. The guidance includes recommended dosing schedules for parenteral administration of Pabrinex (ascorbic acid, anhydrous glucose, nicotinamide, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride) in the treatment of Wernicke- Korsakoff syndrome and also for prophylaxis in at risk patients. This guidance provides information on the prescribing of vitamin and mineral supplements for patients with decompensated liver disease. UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503 - i -

Group/Individual responsible for this document: Policy statement: Clinical Pharmacist It is the responsibility of supervisory staff at all levels to ensure that their staff are working to the most up to date and relevant policies, protocols procedures. By doing so, the quality of the services offered will be maintained, and the chances of staff making erroneous decisions which may affect patient, staff or visitor safety and comfort will be reduced. Responsibilities for ensuring registration of this document on the NHS Grampian Information/ Document Silo: Lead Author/Co-ordinator: Clinical Pharmacist Physical location of the Pharmacy and Medicines Directorate, Westholme original of this document: Job title of creator of this Clinical Pharmacist document: Job/group title of those who Consultant Gastroenterologists, Aberdeen Royal Infirmary have control over this document: Responsibilities for disseminating document as per distribution list: Lead Author/Co-ordinator: Clinical Pharmacist Responsibilities for implementation: Organisational: Operational Management Team and Chief Executive Sector General Managers, Medical Leads and Nursing Leads Departmental: Clinical Leads Area: Line Manager Review frequency and date of next review: Every two years November 2013 Responsibilities for review of this document: Lead Author/Co-ordinator: Clinical Pharmacist Revision History: Revision Date Previous Revision Date Summary of Changes (Descriptive summary of the changes made) Changes Marked* (Identify page numbers and section heading ) * Changes marked should detail the section(s) of the document that have been amended, i.e. page number and section heading. UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503 - ii -

Contents Introduction...2 Thiamine Supplementation in Wernicke-Korsakoff Syndrome...2 Treatment of acute Wernicke-Korsakoff syndrome...2 Prophylaxis treatment for patients at high risk of Wernicke-Korsakoff syndrome...4 Prophylaxis treatment for patients at low risk of Wernicke-Korsakoff syndrome...4 Vitamin and mineral supplementation in patients with decompensated liver disease...4 Refeeding syndrome...5 References...5 Distribution list...6 Appendix 1: Flowchart For The Prescribing Of Thiamine Supplementation For Prophylaxis And Treatment Of Wernicke-Korsakoff Syndrome...7 UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-1 -

NHS Grampian (Acute Sector) Guidance For The Prescribing Of Vitamin And Mineral Supplements For Hospitalised Patients With A History Of Excess Alcohol Consumption Introduction Micronutrient deficiencies are common in people with a history of chronic alcohol consumption. This can be due to a decrease in absorption, storage capacity and/or metabolism of vitamins into their active forms. Thiamine Supplementation in Wernicke-Korsakoff Syndrome. Wernicke-Korsakoff Syndrome is a relatively common condition seen in patients with a history of chronic alcohol consumption resulting from thiamine deficiency. It is known to cause significant morbidity and mortality and untreated will cause irreversible brain damage and progress steadily to death. Early recognition of symptoms and treatment is vital as symptoms may be controlled and progression of the syndrome can be slowed or halted. Thiamine has been established as the treatment of choice for over 50 years, however, there is uncertainty about appropriate dosage, frequency, duration or route of administration due to lack of randomised controlled trials. Current practice guidelines are based on case reports and clinical experience. As classic signs of Wernicke s Encephalopathy may occur in only 10% of patients a presumptive diagnosis should be made for all patients with a history of alcohol excess and/or current intoxication with one or more of the following otherwise unexplained symptoms: Confusion Delirium Ataxia, especially truncal ataxia Ophthlmoplegia Nystagmus Memory disturbance Hypothermia and hypotension Coma/unconsciousness. Treatment of acute Wernicke-Korsakoff syndrome Immediate treatment with Intravenous thiamine supplementation is required for people with suspected Wernicke s Encephalopathy. The first choice of treatment is Pabrinex Intravenous High Potency (IVHP) 5mL ampoules 1 and 2 (ascorbic acid UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-2 -

500mg, anhydrous glucose 1g, nicotinamide 160mg, pyridoxine hydrochloride 50mg, riboflavin 4mg, thiamine hydrochloride 250mg). The contents of two pairs of Pabrinex IVHP 5mL ampoules should be administered three times daily for two days. If there is no clinical response after two days (six doses), treatment should be discontinued. If clinical improvement is seen the contents of one pair of 5mL Pabrinex IVHP ampoules should then be administered three times daily for a further three days or for as long as clinical improvement continues. Anaphylaxis is a rare complication of Pabrinex administration that may occur during or shortly after parenteral administration. It is more likely to occur with the intravenous route than the intramuscular route. It is recommended that parenteral administration is restricted to patients in whom it is essential. For intravenous administration one to two 5mL pairs of Pabrinex IVHP (ampoules 1 and 2) must be mixed and diluted with 50-100mL sodium chloride 0.9% or glucose 5% and infused over 30 minutes. The patient should be observed for signs of anaphylaxis throughout the infusion where suitable facilities with epinephrine (adrenaline) 1 in 1000 (1mg in 1mL) for intramuscular administration are readily available. Repeated injections of preparations containing high concentrations of thiamine may give rise to anaphylactic shock. Mild allergic reactions such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Pabrinex is also available as an Intramuscular High Potency Injection. The intravenous and intramuscular formulations are not interchangeable. The intramuscular preparation may be prescribed if intravenous administration is not suitable or unavailable. Please refer to the Pabrinex Intramusular High Potency Injection Summary of Product Characteristics for details on dosage and method of administration. Following the initial five day intravenous treatment, oral supplementation should begin with thiamine 100mg three times daily. This should be reviewed prior to discharge. If the patient is at risk of malnutrition and continues to consume alcohol then treatment with oral thiamine 100mg three times daily should be taken indefinitely. Patients who remain abstinent from alcohol and have a well balanced diet should continue oral thiamine 100mg three times daily for up to three months. A longer duration of treatment may be justified in some circumstances and should be reviewed by the patient s General Practitioner (see Appendix 1 for flowchart). UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-3 -

Prophylactic treatment for patients at high risk of Wernicke-Korsakoff syndrome Patients at high risk of Wernicke-Korsakoff syndrome are those who drink alcohol to excess, especially those who consume greater than 20 units per day, and may have symptoms/signs of: Diarrhoea Nausea/vomiting Poor diet Weight loss or malnutrition Concerns regarding gastrointestinal absorption. Treatment with intravenous thiamine is indicated for patients at high risk of Wernicke- Korsakoff syndrome. The contents of one pair of Pabrinex IVHP 5mL ampoules should be administered three times daily for two days. Following the initial intravenous loading dose, oral supplementation should begin with thiamine 100mg three times daily. This should be reviewed prior to discharge. If the patient is at risk of malnutrition and continues to consume alcohol then treatment with oral thiamine 100mg three times daily should be taken indefinitely. Patients who remain abstinent from alcohol and have a well balanced diet should continue oral thiamine 100mg three times daily for up to three months. A longer duration of treatment may be justified in some circumstances and should be reviewed by the patient s General Practitioner (see Appendix 1 for flowchart). Prophylactic treatment for patients at low risk of Wernicke-Korsakoff syndrome Patients who are at low risk of developing Wernicke-Korsakoff syndrome are those who have a history of excess alcohol consumption with recent alcohol intake (in the last three weeks) and not exhibiting any signs or symptoms as discussed above. Treatment with oral thiamine is indicated for these patients. Oral supplementation should be prescribed as thiamine 100mg three times daily. This should be reviewed prior to discharge. If the patient is at risk of malnutrition and they continue to consume alcohol then treatment with oral thiamine 100mg three times daily should be taken indefinitely. Patients who remain abstinent from alcohol and have a well balanced diet should continue oral thiamine 100mg three times daily for up to three months. A longer duration of treatment may be justified in some circumstances and should be reviewed by the patient s General Practitioner (see Appendix 1 for flowchart). Vitamin and mineral supplementation in patients with decompensated liver disease Patients with decompensated liver disease with signs of malnourishment or a Malnutrition Universal Screening Tool score (MUST) 2 should be prescribed one Forceval capsule once daily (one hour after a main meal) or an equivalent balanced multivitamin and mineral supplement. Abidec (0.6mL once daily) multivitamin drops may be prescribed for patients who have difficulty swallowing capsules and may be administered via an enteral feeding tube. UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-4 -

Signs of decompensated liver disease include encephalopathy, ascites, oedema, variceal bleeding and impaired synthetic function (low albumin, elevated bilirubin and prolonged prothromin time). There is little evidence to substantiate the use of Vitamin B Compound Strong tablets for patients with decompensated liver disease with signs of malnourishment or MUST 2 or those with suspected Wernicke-Korsakoff syndrome and should therefore NOT be prescribed. Refeeding syndrome Patients who are at risk of refeeding syndrome should be monitored as per NHS Grampian Refeeding syndrome guideline and any biochemical abnormalities should be corrected. Detailed NHS Grampian guidelines for the treatment of hypokalaemia, hypocalcaemia and hypomagnesaemia are available on the intranet or pharmacy (01224 552316) may be contacted for advice. References Baines M, Bligh JG, Madden JS. Tissue thiamin levels of hospitalised alcoholics before and after oral or parenteral vitamins. Alcohol & Alcoholism. 1988; 23(1):49-52 British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 61st ed. London: UK: BMJ Group and RPS Publishing; 2011 Cook CC, Hallwood PM, Thomson AD. B vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. [Review] [127 refs]. Alcohol & Alcoholism. 1998; 33(4):317-336 Cook CC, Henry JA, Thomson AD, Touquet R. The Royal College of Physicians Report on Alcohol: Guidelines for managing Wernicke s Encephalopathy in the accident and emergency department. Alcohol & Alcoholism 2002; 37(6): 513-521 Day E, Bentham P, Callaghan R, Kuruvilla T, George S. Thiamine for Wernicke- Korsakoff Syndrome in people at risk from alcohol abuse. Cochrane Database of Systematic Reviews 2004, Issue 1 Marshall EJ, Thomson AD. The natural history and pathophysiology of Wernicke s Encephalopathy and Korsakoff s Psychosis. Alcohol & Alcoholism 2006; 41(2); 151-158 National Institute for Health and Clinical Excellence (NICE), Alcohol-use disorders. Diagnosis and clinical management of alcohol-related physical conditions (CG100). June 2010 Royal College of Physicians. Alcohol - can the NHS afford it? Recommendations for a coherent alcohol strategy for hospitals. A report of a working party of the Royal College of Physicians. Royal College of Physicians, 2001 UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-5 -

Scottish Intercollegiate Guidelines Network (SIGN), 2003 (74): The Management of Harmful Drinking and Alcohol Dependence in Primary Care. Summary of Product Characteristics: Pabrinex Intravenous High Potency Injection http://www.medicines.org.uk/emc/medicine/6571/spc/pabrinex +Intravenous+High +Potency+Injection/ Taylor D, Paton C, Kapur S. The South London and Maudsley NHS Foundation Trust Oxleas NHS Foundation Trust Prescribing Guidelines. 10th Ed. Informa Healthcare. London. 2009. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol & Alcoholismsupplement. 2000; 35(1):2-7 Distribution list All Acute Sector NHS Grampian Clinical Staff. UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-6 -

Appendix 1 Flowchart For The Prescribing Of Thiamine Supplementation For Prophylaxis And Treatment Of Wernicke-Korsakoff Syndrome This flowchart should be used in conjunction with the accompanying guideline. Low risk Assess patient for signs and symptoms of Wernicke- Korsakoff Syndrome High risk Administer ONE pair of Pabrinex IVHP ampoules THREE times daily for 2 days Signs and symptoms of Wernicke- Korsakoff Syndome present Administer TWO pairs of Pabrinex IVHP ampoules THREE times daily for 2 days Clinical response? Yes No Enteral route available? Administer ONE pair of Pabrinex ampoules THREE times daily for a further THREE days or for as long as improvement continues Discontinue Pabrinex IVHP supplementation Yes No Oral thiamine 100mg THREE times daily Review at discharge Administer ONE pair of Pabrinex IVHP ampoules ONCE daily until enteral route available Is patient at risk of malnourishment and likely to continue to consume alcohol? No Oral thiamine 100mg three times daily for up to 3 months Yes Oral thiamine 100mg three times daily long term IMPORTANT RISK OF ANAPHYLAXIS-Pabrinex must only be administered where suitable facilities and epinephrine (adrenaline) 1in 1000 (1mg/mL) for intramuscular injection is readily available. There are two formulations of Pabrinex injection, one for IV and one for IM use. These are NOT interchangeable. To administer Pabrinex IVHP ampoules, mix the contents of ampoule 1 and 2 with 50-100ml sodium chloride 0.9% and infuse over 30 minutes. UNCONTROLLED WHEN PRINTED Review Date: November 2013 Identifier: NHSG/Guid/VitSupAC/MGPG503-7 -